<DOC>
	<DOCNO>NCT02944799</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled trial include 160 consecutive patient diagnose rheumatoid arthritis ( RA ) osteoporosis treat alendronate ( ALN ) five year . Patients randomized discontinuation continuation alendronate . Outcomes measure use dual energy absorptiometry ( DXA ) , High Resolution peripheral Quantitative Computer Tomography ( HR-pQCT ) biochemical marker bone metabolism inflammation 6 month , 1 2 year .</brief_summary>
	<brief_title>Alendronate Treatment Osteoporosis Rheumatoid Arthritis</brief_title>
	<detailed_description>Primary objective : - ass effect discontinuation alendronate ( ALN ) C-terminal telopeptide crosslinks ( CTX ) Type 1 procollagen amino-terminal-propeptide ( P1NP ) 6 month - ass effect discontinuation ALN bone mineral density ( BMD ) DXA scan 2 year Secondary objective : - ass effect discontinuation ALN vBMD HRpQCT scan 2 year - ass effect discontinuation ALN biochemical marker bone metabolism 6 24 month - evaluate compare change vBMD cancellous cortical bone respectively , discontinuation ALN - evaluate correlation RA activity measure DAS28-CRP bone metabolism Interventions : Participants randomize one two group : - Group 1 ( Alendronate group , N=80 ) : alendronate 70mg/weekly , calcium 800 mg/day vitamin D 38 µg/day - Group 2 ( Placebo group , N=80 ) : alendronate-placebo , calcium 800 mg/day vitamin D 38 µg/day Concomitant treatment RA : Patients include trial treat accord national Danish guideline treatment RA Assignment intervention : The Hospital Pharmacy Aarhus carry randomization . Using web-based programme randomization.com list distribution produce . The randomization stratify accord type treatment patient receive RA . All patient receive traditional DMARDs methotrexate , sulfasalazine , hydroxychloroquine , leflunomide combination hereof allocate grop A . All patient receive kind biological treatment ( bDMARDs ) e.g . infliximab allocate group B . When request randomization hospital pharmacy , investigator note patient group A B . Both group A B undergo randomization 1:1 ALN placebo group , use block randomization block 6 . Participant timeline : Patients see screen visit , baseline 3 , 6 , 12 , 24 month Procedures screen : informed consent procedure , full medical history , full physical examination , 12- lead EKG , screen blood sample , DXA scan Procedures visit : focused physical exam joint back , measurement blood pressure , pulse temperature , calculation DAS28-CRP HAQ score , screen adverse event , routine project blood sample . At baseline visit : HRpQCT scan Xrays hand foot At visit 12 month : DXA HRpQCT scan At visit 24 month : DXA HRpQCT scan , xrays hand foot Clinical laboratory test : - routine analysis include : alkaline phosphatase , creatinine , alanine aminotransferase ( ALT ) , platelet count , Hemoglobin , white blood cell , absolute neutrophil count , absolute lymphocyte count , CRP ( total 8ml ) - screen analysis : routine analysis well s-FSH and/or HCG ( woman ) , calcium , PTH , vitamin-D status , TSH ( total 16 ml ) - primary project analyse include : CTX P1NP ( total 4 ml ) - secondary project analysis include : bone specific alkaline phosphatase , RANK-L , sclerostin , tumor necrosis factor , osteoprotegrin , P1NP , osteocalcin , IL-6 , IL-17 ( total 8 ml ) - extra blood bank sample - 3ml serum , 2 ml plasma full blood storage later analysis DXA scan : Study participant scan use Hologic discovery machine.To ensure comparative result , machine use participant scan . Lumbar spine anterior-posterior leave hip picture record follow local guideline . HR-pQCT scan : Bone structure measure metacarpal 2-4 proximal radius use model XTREME CT-I SCANCO MEDICAL AG ; SCHWEIZ . A 2,7 cm long area right hand second third metacarpophalangeal joint scan . After 0,9 cm long part distal radius scan The 3D dataset analyze number volume erosion calculate . Volumetric BMD calculate cortical trabecular bone , trabecular number separation accord built-in software . X-rays hand foot : Standardized X-rays hands/forearms upper foot separate AP ( dorsopalmar ) projection hand wrist dorsoplantar projection foot Images hand center around 2nd 3rd MCPjoints The foot must tilt case suboptimal projection MTP-joints . All image score centrally accord Sharp-van der Heide score system . DAS28-CRP : A clinical activity score arthritis activity calculate mean - number tender swollen joint score include follow twenty eight joint : shoulder , elbow , wrist , metacarpophalangeal joint , proximal interphalangeal joint knee . - crp-measurement - general health assessment doctor use VAS-scale A number 0 10 calculate . Values &lt; 2,6 consider remission , value &gt; 2,6 consider evidence disease activity Harms : The dose radiation estimate 0,07mSievert , HR-pQCT scan contributes 0,012mS , DXAscan 0,01mS Xray status hand foot 0,008mS . The average annual background radiation exposure Denmark 3mSievert . Thus participant receive increase radiation dose correspond 9 day background radiation . The HR-pQCT-scans require fixation hand 8 3 minute respectively , might cause slight discomfort . Safety measure : All routine biochemical marker ( visit 1-5 ) analyze evaluate promptly . An increase alkaline phosphatase 100 % lead participant call extra visit evaluation cause . The patient withdrawn study suspicion accelerate bone loss . All fracture record case low-energy fracture patient withdrawn study . The 12 month DXA scan review BMD decrease 5 % lead exclusion study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Patients ( &gt; 18 year ) rheumatoid arthritis accord ACR ( 1987 2010 ) /EULAR ( 2010 ) classification criterion ( 12 ) Diagnosed osteoporosis BMD le equal to2,5 hip and/or lumbar spine treat alendronate five year current Tscore DXA well equal 2,5 ( femoral ) 3,0 ( vertebral ) receive treatment outpatient basis negative pregnancy test ( serum HCG ) prior trial start use contraception throughout study period 1 month conclusion study period woman childbearing potential . Plasma T1/2 ALN le 2 hour . The forms contraception include : intrauterine device ( IUD ) hormonal anticontraceptives ( contraceptive pill , implant , patch injection vaginal ring ) . Sterile nonfertile participant use contraception . Sterile nonfertile define undergone surgical sterilization ( vasectomy / bilateral tubectomy , hysterectomy bilateral oophorectomy ) postmenopausal status , define absence menstrual period least 12 month prior enrollment . Postmenopause confirm measurement sFSH prior enrollment . ability willingness give write informed consent meet requirement trial protocol . history spine hip fracture due osteoporosis history nonvertebral fracture ( finger toe include ) within last 5 year osteonecrosis jaw . history ongoing systemic GC treatment within last 6 month ( intraarticular injection approve ) know allergy toward component study medicine prior ongoing treatment antiosteoporosis drug hormone replacement therapy teriparatide evidence malignant disease metabolic bone disease osteoporosis hypo hyperthyroidism hypocalcaemia impair renal function ( eGFR &lt; 35ml/min ) know disease esophagus might impair ability swallow tablet achalasia , dysphagia stricture history upper gastrointestinal disease within 1 year prior enrollment peptic ulcer , upper GI bleeding , gastritis , duodenitis surgical procedure upper GItract allergy towards substance study medicine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>